Appendicitis caused by the metastasis of HER2-positive breast cancer

被引:1
|
作者
Mori, Ryutaro [1 ]
Futamura, Manabu [1 ]
Morimitsu, Kasumi [1 ]
Yoshida, Kazuhiro [1 ]
机构
[1] Gifu Univ, Grad Sch Med, Dept Surg Oncol, 1-1 Yanagido, Gifu 5011194, Japan
来源
SURGICAL CASE REPORTS | 2016年 / 2卷
关键词
Secondary appendiceal neoplasm; Appendicitis; Lobular carcinoma;
D O I
10.1186/s40792-016-0235-5
中图分类号
R61 [外科手术学];
学科分类号
摘要
The appropriate therapy for metastatic breast cancer must be selected based on the immunohistochemical phenotype of the cancer. However, biopsy for metastatic lesions is difficult. We herein report a patient with incidental appendicitis caused by a metastatic breast cancer which was successfully treated with effective therapy chosen based on the pathological diagnosis obtained on resection. The patient was a 56-year-old female with right breast cancer and an immunohistochemical status of estrogen receptor (ER) (+), progesterone receptor (PgR) (+), human epidermal growth factor receptor 2 (HER2) (3+), and Ki67 40 %. She received epirubicin and cyclophosphamide therapy followed by docetaxel and trastuzumab, and total mastectomy with axillary dissection was performed. Thereafter, she received postmastectomy radiation, adjuvant trastuzumab, and adjuvant hormone therapy with letrozole. One year and 8 months after the operation, she developed right hydronephrosis and swollen para-aortic lymph nodes and her hormone therapy was changed to fulvestrant therapy. However, she additionally developed left hydronephrosis and multiple bone metastases, and pertuzumab, trastuzumab, and docetaxel therapy was started. After six cycles, her disease became well-controlled, and maintenance with pertuzumab and trastuzumab was introduced. However, after another 7 months, she developed new vertebral metastasis and acute appendicitis and laparoscopic appendectomy was performed. A pathological investigation of the resected appendix revealed some clusters of atypical cells in the subserosa and muscle layer, which showed an immunohistochemical status of ER (+), PgR (-), HER2 (3+), and E-cadherin (-). These findings led to the diagnosis as appendiceal metastasis of invasive lobular carcinoma (ILC) from the breast. Thereafter, she received trastuzumab-DM1 and her disease was well-controlled again. Appendicitis caused by breast cancer is very rare. However, ILC sometimes develops metastases in the abdominal cavity; an appendiceal tumor should therefore be included in the differential diagnosis. A pathological diagnosis of metastatic tumor could be very useful for selecting the effective therapy.
引用
收藏
页数:5
相关论文
共 50 条
  • [41] Cardiotoxicity in HER2-positive breast cancer patients
    Diana Gonciar
    Lucian Mocan
    Alexandru Zlibut
    Teodora Mocan
    Lucia Agoston-Coldea
    Heart Failure Reviews, 2021, 26 : 919 - 935
  • [42] Frontiers in HER2-positive breast cancer in 2020
    Peddi, Parvin F.
    Slamon, Dennis J.
    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2021, 33 (01) : 48 - 52
  • [43] Current challenges in HER2-positive breast cancer
    Puglisi, Fabio
    Fontanella, Caterina
    Amoroso, Vito
    Bianchi, Giulia Valeria
    Bisagni, Giancarlo
    Falci, Cristina
    Fontana, Andrea
    Generali, Daniele
    Gianni, Lorenzo
    Grassadonia, Antonio
    Moscetti, Luca
    Portarena, Ilaria
    Rossi, Emanuela
    Marchetti, Paolo
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 98 : 211 - 221
  • [44] Adjuvant Trastuzumab in HER2-Positive Breast Cancer
    Mortimer, Joanne
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (07): : 662 - 663
  • [45] Preoperative treatment of HER2-positive breast cancer
    Wysocki, Piotr J.
    Krzakowski, Maciej
    ONCOLOGY IN CLINICAL PRACTICE, 2020, 16 (02): : 69 - 74
  • [46] HER2-positive male breast cancer: an update
    Ottini, Laura
    Capalbo, Carlo
    Rizzolo, Piera
    Silvestri, Valentina
    Bronte, Giuseppe
    Rizzo, Sergio
    Russo, Antonio
    BREAST CANCER-TARGETS AND THERAPY, 2010, 2 : 45 - 58
  • [48] Adjuvant trastuzumab for HER2-positive breast cancer
    Spicer, J
    Harries, M
    Ellis, P
    LANCET, 2005, 366 (9486): : 634 - 634
  • [49] Trastuzumab emtansine for HER2-positive breast cancer
    Venkatesan, Priya
    LANCET ONCOLOGY, 2016, 17 (12): : E528 - E528
  • [50] Her2-positive breast cancer: Herceptin and beyond
    Dean-Colomb, Windy
    Esteva, Francisco J.
    EUROPEAN JOURNAL OF CANCER, 2008, 44 (18) : 2806 - 2812